Goals. A study of the efficacy and safety of EndoClot ™ in combination with traditional methods of endoscopic hemostasis. Methods. The study included 62 clinical observations of patients with UGDB, that treated at the CCH named after S.P. Botkin in the period from June 2015 to September 2016. The analysis does not include clinical observations of patients without received endoscopic treatment. The equilibration of men and women is 2.3: 1 (43 and 19, respectively). The age of the patients varied from 35 to 87 years (average age 64.3 ± 10.7 years). The elderly patients (n = 29, –46.8%) and senile (n = 17, –27.4%) aged predominated (74.2%). Results. In carried out the TCEG, the primary hemostasis was 100% effective in patients with UGDB, exceeding this level in DCEG 96.8% : in the observation group after TCEG, bleeding recurrence developed in 2 (6.7%) cases, in the group after DCEG — in 6 (19.3%). During bleeding from acute ulcers, the frequency of the SC after DCEG was 20.0%, and after TCEG there was no recurrence of bleeding. After bleeding from chronic ulcers SC developed in 3 (18.8%) and 2 (10,5%) cases, respectively. The time of occurrence SC in the groups with DCEG and TCEG was significantly different: after DCEG, SC developed within the first 2 days, and after TKEG — on the 4th and on the 5th day after successful primary endoscopic hemostasis. Thus, recurrences of bleeding were early after a successful DCEG (developed within the first 48 hours after endoscopic hemostasis), and after successful primary TCEG — late (developed after 48 hours), according to the classification of V.K. Gostishcheva and M.A. Evseev (2010) [1]. As a rule, two factors can development the early SC: the efficiency of endoscopic hemostasis and the adequacy of antiulcer pharmacotherapy. In our study, with initially comparable anti-ulcer therapy in both groups, the clinical observations of patients with UGDB differed only in the way of performed endoscopic hemostasis. Late SC is caused by ischemic necrosis of periulcerous tissues and timely preventive surgical intervention is necessary for their avoidance. Consequently, the EndoClot ™ application in the TCEG was most effective in bleeding from acute ulcers, as evidenced — the absence of SC in this group, compared with 20.0% of the SC after a successful primary DCEG. In case of bleeding due to a complicated peptic ulcer, TCEG was less effective: there was a decrease in the incidence of SC from 18.8% to 10.5%, after a successful primary DCEG. The differences discussed above are explained by differences in the etiopathogenesis of acute and chronic ulcers. Conclusion: EndoClot ™ has proved as an effective, safe and perspective component of CEG. Direction them as part of the TCEG enabled in most cases to achieve a steady stop of gastroduodenal ulcer bleeding (93.3%), to reduce the SC incidences from 19.3% to 6.7% and operative activity from 16.1% to 6.7% . EndoClot ™ has proven as the most effective for ulcerative gastroduodenal bleeding, therefore, with bleeding caused by acute ulcers, it is justified to use EndoClot ™ as one of the components of TCEG. But, according to opinion of V. I. Nikolsky et al. (2009) [4], treatment of patients with acute gastroduodenal ulcers should be etiopathogenetic, and measures aimed for stopping / preventing bleeding should be combined with parallel rational therapy of the underlying disease and its complications.